Varian Launches IntelliBlate in Europe for Soft Tissue Tumor Treatment

July 18, 2025—Varian, a Siemens Healthineers company, recently announced the European launch of its next-generation IntelliBlate microwave ablation solution, which has received CE Mark approval for the minimally invasive treatment of soft tissue tumors.

The company will introduce IntelliBlate to clinicians at CIRSE 2025. In the United States, IntelliBlate received FDA market clearance in 2024, noted Varian.

With the addition of IntelliBlate, the Varian and Siemens Healthineers’ imaging and software solutions allow clinicians to plan, place, treat, monitor, and confirm ablation therapy in one environment, noted the press release.

Varian stated that IntelliBlate produces large, controlled spherical ablation zones for predictable treatment delivery. Its Ximitry probe’s thermocouples provide continuous temperature monitoring inside and outside the ablation zone, allowing clinicians to observe real-time temperature changes and make informed decisions.

The company noted that the large, international COLLISION phase 3 trial demonstrated that thermal ablation can be as effective as the gold standard of surgical resection alone in treating small-size colorectal liver metastases while resulting in significantly fewer complications, comparable overall survival, and shorter hospital stays for patients.

The COLLISION findings were published by Susan van der Lei, MD, et al in The Lancet Oncology (2025;26:187-199).